The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.
The funding is being provided by the Flemish government's Agency for Innovation and Entrepreneurship to support the three-year development project.
OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.
The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.
The partners will use Biolidics' circulating tumor cell retrieval system to evaluate the cells' utility as biomarkers of patient response to cancer treatment.
The company said it will use the funds to repay the $75 million outstanding under its 2018 Note Purchase Agreement, to expand internationally, and on general operations.
The health technology firm is proposing a new software solution that would standardize coding in genetic testing, but a more predictable system would also narrow variability in test pricing.
The test is the first near-patient assay for M. genitalium, and can also guide treatment by detecting antibacterial resistance markers.
New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.
The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.
The French metagenomic sequencing firm received funding from both historical and new investors, including debt financing from Norgine Ventures.
OncoCyte believes Razor's CLIA-validated lung cancer prognostic test will complement its in-development DetermaVu lung cancer detection assay.
The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
Clinical applications grew 11 percent driven by 34 percent growth in the molecular biology segment, including a 31 percent spike in FilmArray product sales.
The combined firm will be based in Gaithersburg, Maryland and will focus on infectious disease diagnostics and antimicrobial resistance prediction services.
The group notes the importance of lab CLIA certification, clear test reports, and clinical validity support for test claims in the literature, guidelines, and FDA labels.
The company reported $10.7 million in total revenues for the quarter and said test report volume for its DecisionDx-Melanoma test grew 27 percent.
A European study, published today in NEJM, used a POC, PCR-based system to perform CYP2C19 genotyping to guide platelet inhibitor therapy.
The company, founded earlier this year, is developing a technology for the detection of low-frequency genetic mutations for diagnostic applications.